Supplementing chemotherapy with PD-1/PD-L1 mAbs has significantly improved the efficacy of front-line treatment for advanced NSCLC as compared with chemotherapy alone and also demonstrated a manageable safety profile. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.